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Host modulation therapy may be effective in controlling the immune response responsible for
periodontal diseases.
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PURCHASE COURSE
This course was published in the March 2020 issue and expires March 2023. The authors have no commercial
con icts of interest to disclose. This 2 credit hour self-study activity is electronically mediated.

EDUCATIONAL OBJECTIVES
After reading this course, the participant should be able to:
1. Discuss the relationship between in ammation and the host response.
2. Identify host modulation therapies used to treat chronic in ammatory diseases.
3. Explain how host modulation therapies may be effective in addressing periodontal diseases.

Periodontal diseases are related to an immunoin ammatory response to various types of oral bio lm. They
1

affect approximately 42% of United States adults. Chronic periodontitis is characterized by alveolar bone
loss, attachment loss, and apical migration of the junctional epithelium. Periodontal diseases result from
dysbiosis: an imbalance between different organisms present in the natural microbiota of the subgingival
microenvironment. Periodontal destruction can be attributed to the interaction of two main players:

1

periodontally pathogenic bio lm and the host-mediated immunoin ammatory response to that bio lm.

Current treatment guidelines for periodontitis include the physical removal of plaque bio lm and calculus by
scaling and root planing.² While this treatment aims to eliminate the bacterial insult, scaling and root planing
does not address the host response element of periodontal diseases.³
In ammation is the body’s initial response to various types of injury via physical, bacterial, or chemical

4,5

means, and is characterized by an increase in temperature, erythema, edema, pain, and loss of function.

During an acute in ammatory response, a series of events occurs including increased vessel permeability,
emigration of leukocytes to the site of injury, and activation of macrophages, which ingest foreign
4,6

substances, toxins, and debris.
4

If the acute injury is eliminated, tissue repair begins in an effort to return to
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4

its original state. If in ammation persists due to continued insult or an exaggerated immune response,
1,6

tissue damage continues.

The chronic in ammatory response involves various cells of the acquired
4,5

immune system: macrophages, lymphocytes, and plasma cells and their products.

The development of

periodontal diseases is initiated by a dysbiotic bacterial plaque insult and tissue destruction is propagated
by the host immune response to the bio lm. This response differs among individuals, which may explain
why some patients have low levels of bacterial plaque deposits and excellent oral hygiene, but still
1,4,7–11

experience chronic in ammation and bone loss.

5

Host modulation therapies address the host immune response to an antigen or antigens. They aim to
disrupt immunoin ammatory pathways within the host’s response to those pathogens that perpetuate an
12

in ammatory response.

Several different pathways can initiate an in ammatory response, including B-

cells, T-cells, and macrophages. They produce pro-in ammatory cytokines or signaling proteins to
coordinate the immune response, resulting in either pro- or anti-in ammatory results. Variations in disease
severity may be due to an increased number of B cells or plasma cells in response to a pathogen and/or an
overproduction of their byproducts, such as matrix metalloproteinases (MMPs), cytokines, prostaglandins
1,7,12,13

(PG), and other in ammatory mediators.

Host modulation therapies are also used to treat other chronic in ammatory diseases, such as rheumatoid
arthritis (RA), Crohn disease, and psoriasis. RA is similar to periodontal diseases in regards to the bone loss
3,6,13,14

and collagen destruction caused by the host in ammatory response.

Treatments for RA include non-

steroidal anti-in ammatory drugs (NSAIDs), steroids, and disease modifying anti-rheumatic drugs (eg,
methotrexates, immunosuppressants, and cytokine-targeting therapies). However, side effects such as liver
damage, nausea, hair loss, rashes, and lung infections typically preclude their use for periodontal disease
5,15

treatment.

Current cytokine-modulation therapies target cytokines common in both RA and periodontitis.

Anakinra, a drug approved for treating RA, is a recombinant, modi ed version of the interleukin-1 receptor
antagonist that competes with the proin ammatory cytokine IL-1 for receptors, therefore preventing or
reducing in ammation. Additionally, in iximab is a monoclonal antibody drug used to neutralize tumor

3

necrosis factor alpha (TNF-α), a pro-in ammatory cytokine implicated in both RA and periodontal diseases.
These treatments are used as adjuncts to traditional immunosuppressive therapy and have limited
effectiveness in reducing symptoms of RA as monotherapies. However, with continued research, these
2,14

pathways may provide future treatment options for both RA and periodontal diseases.

HOST MODULATION THERAPY OPTIONS FOR PERIODONTAL DISEASES
A variety of potential host-modulation therapies are available to treat periodontal diseases, including
NSAIDs, subantimicrobial-dose doxycycline (SDD), bisphosphonates, and cytokine inhibitors (Table 1).
However, most of these therapies are not yet proven or approved treatments for periodontitis. NSAIDs
regulate the host response by decreasing PGs, pro-in ammatory hormones that demonstrate local
upregulation in response to lipopolysaccharides (LPS) present in plaque bio lm. NSAIDs are known to be
direct inhibitors of cyclooxygenase, an enzyme involved in tissue breakdown via the production of
4,7,8,16

arachidonic acid metabolites that lead to activation of osteoclasts and MMPs.

While NSAIDs are
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incorporated into regular periodontal treatment.

A recent systematic review revealed clinical bene ts for

the use of NSAIDs in conjunction with nonsurgical periodontal treatment in reducing the rate of gingival
in ammation and alveolar bone resorption. However, these bene ts did not extend to the improvement of
9

probing depth or clinical attachment level. Unwanted side effects may also be reduced by the use of novel
17

NSAID therapies, NSAID dentifrices, and/or lower dose NSAIDs.

18

Geisinger et al

concluded that the

addition of low‐dose aspirin therapy in patients with chronic periodontitis undergoing nonsurgical
periodontal therapy was bene cial. Aspirin reduces in ammatory mediators and triggers production of
resolvin D3, an in ammation resolving mediator derived from the metabolism of omega-3 fatty acids, by
modifying cells’ production of cyclo-oxygenase type 2, another in ammation-inducing PGs. Additional
studies on the use of adjunctive aspirin therapy in the treatment of periodontal diseases are needed.

Administration of SDD helps to reduce MMP activity, thus preventing collagen destruction in periodontal
7,19

diseases.

Tetracyclines have been used as antimicrobials in higher doses to reduce bacterial load but

also promote antibiotic resistance at these dosages. In the treatment of periodontal diseases, a
subantimicrobial dose reduces in ammation via pathways unrelated to antimicrobial activity, thus they do
19,20

not result in antibiotic resistance.

In health, MMPs are secreted by broblasts, keratinocytes, macro-

phages, polymorphonuclear leukocytes, and endothelial cells, and support normal connective tissue and

7,20

bone remodeling. In disease, overproduction of MMPs can lead to collagen destruction and bone loss.

Tetracyclines have been shown to increase levels of transforming growth factor β1 (TGF-β) in the gingival
crevicular uid, which is an important mediator in wound healing that stimulates broblast proliferation and
7,20,21

also inhibits MMPs.

SDD treatment has few side effects, can help reduce in ammation, improves
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treatment outcomes, and is recommended by the American Dental Association as an adjunct for the
nonsurgical treatment of moderate to severe chronic periodontitis in conjunction with scaling and root
2,19

planing.

Bisphosphonates are bone-sparing agents that modify the host response by disrupting osteoclastic activity,
which inhibits bone resorption. Bone sparing drugs are used to treat metabolic bone diseases but are not
recommended for the treatment of periodontal diseases. In addition to disrupting osteoclastic activity,
bisphosphonates also induce osteoclastic apoptosis (programmed cell death), and may also inhibit MMP
7,8,16,17

activity or provide anti-collagenase properties.

22

Lane et al

found that bisphosphonates provided

bene ts in clinical attachment levels, probing depths, and bleeding on probing. Despite this promising study,
bisphosphonates are not without side effects, including changes in white blood cell production and, rarely,
medication-related osteonecrosis of the jaw. They are currently only approved for systemic bone loss by the
US Food and Drug Administration (FDA). However, future incarnations of bisphosphonates may be used to
7,16,17

treat periodontal bone loss.

Host modulation therapies that target speci c cytokine pathways are used as second-line therapies for RA
5,23

and may be helpful in periodontitis treatment.

Microbes produce a variety of pathogenic substances

including glycoproteins, lipoproteins, lipoteichoic acids, viral ribonucleic acids (RNA), and
lipopolysaccharides. These substances are recognized by a family of receptors known as toll-like receptors
that are membrane-spanning proteins found on macrophages, monocytes, and dendritic cells. They activate
a cascade of intracellular signaling molecules, including mitogen activated protein kinases (MAPKs) and
transcription factors such as nuclear factor-kB (NF-kB). These cell signaling molecules and transcription
24–27

factors ultimately lead to the production of pro-in ammatory cytokines.

15,28

cytokine inhibition by the use of antibodies or fusion proteins to TNF-α.

Early research focused on

Several of these TNF-α inhibitors

were approved by the FDA for use in RA due to their ability to slightly decrease bone resorption and increase
10,23

bone formation.

5,15,23

suppression.

However, side effects include increased rates of infection and bone marrow

A systematic review of TNF-α inhibitors used in patients with RA and its effect on

periodontitis revealed that those taking TNF-α inhibitors may have reduced progression of periodontal
15

disease and reduced periodontal TNF-α levels.

This topic warrants further research.

The direct targeting of intracellular cell signaling proteins involved in the production of pro-in ammatory
molecules is another approach. MAPKs are a family of intracellular-signaling molecules activated by
28

cytokines or LPS, and result in upregulation of pro-in ammatory cytokines, MMPs, and PGs.
29

clinical trials of P38 MAPK inhibitors have shown promising results in the short term.

Phase II

Another potential

avenue for intracellular host modulation is the Janus kinase/signal transducers and activators of
transcription (JAK/STAT) signal transduction pathway stimulated by cytokines and growth factors.

8,30

Dysregulation of the JAK/STAT pathway can lead to chronic in ammatory diseases and blood cancers.
One of the challenges surrounding the study of cell-signaling protein inhibitors is that the cascade of

proteins involved in cell signaling pathways are often involved in cross-talk with each other, thus activation
31

of one pathway can lead to simultaneous activation of another pathway.
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EMERGING TREATMENTS THAT MAY TARGET PERIODONTITIS
The host modulatory system can be targeted via transcription factors activated by the in ammatory
response. Transcription factors are proteins that bind to deoxyribonucleic acid- or DNA-promoters, and
32

regulate gene activation.

NF-kB is a family of transcription factors activated by pro-in ammatory cytokines
33

and helps to produce additional pro-in ammatory cytokines.

This leads to chronic in ammation. Current

research has led to phase II clinical trials on several different drugs that target the NF-kB pathway in patients
34

with RA.

A study of patients with healthy vs periodontally involved tissues showed an upregulation of NF-

kB in diseased states, suggesting that therapeutic targeting of NF-kB may help improve the immune34,35

mediated component of periodontal diseases.

Several other proteins within the cell signaling pathway
5,7,8

may yield future treatment options but research is currently limited.

The cellular/molecular mechanisms underlying the anti-in ammatory effect of polyunsaturated fatty acids
(PUFA) are unknown, but their use as host modulatory agents is promising. The predominant PUFAs are the
n-6 series (found in soy, corn and sun ower oils) and n-3 series (found mainly in oily sh, although there are
plant sources), also known as omega-3 fatty acids. The three types of omega−3 fatty acids are α-linolenic
acid, eicosapentaenoic acid, and docosahexaenoic acid. Consuming sh-derived omega−3 fatty acids
36

lowers blood markers of in ammation.

In a study of 80 subjects, researchers examined the effectiveness

of combining omega-3 fatty acids and aspirin to treat periodontitis. All subjects received scaling and root
planing, but the subjects in the sh oil/aspirin group received daily supplementation of sh oil and 81 mg of
aspirin. After 3 months and 6 months, subjects in the sh oil/aspirin group exhibited reduction in probing
37

depths, attachment gain, and reductions of salivary biomarkers of bone resorption.

Statins lower cholesterol in the blood by inhibiting the synthesis of mevalonate, the precursor of cholesterol.
Statins have also demonstrated anti-in ammatory and immunomodulatory effects (inhibit tissue-degrading
enzymes) and interfere with osteoclasts. Currently, statins are used to treat osteoporosis and have been
38

used to enhance bone formation and reduce in ammation in dentistry.

Statins seem to increase

production of mRNA of osteoprotegerin by osteoblasts, thereby reducing bone resorption. A recent metaanalysis showed that application of locally applied statins as an adjunct to mechanical periodontal
treatment produced larger improvements in terms of periodontal depth reduction and gain of clinical
39

attachment.

However, little research is available on the use of statins as an adjunct to conventional

periodontal therapy and further research is needed.
Teriparatide, a form of parathyroid hormone (PTH), has been approved by the FDA for the treatment of
osteoporosis. PTH increases serum calcium, and chronically elevated PTH will deplete bone stores.
40

However, intermittent exposure to PTH will activate osteoblasts more than osteoclasts.

41

Bashutski et al

conducted a trial of 40 adults with chronic periodontitis who underwent periodontal surgery and daily
injections of teriparatide. The treatment group experienced greater radiographic resolution of periodontal
bone defects compared to the placebo group, with accelerated osseous wound healing in the oral cavity.
42

Teriparatide joins the growing list of agents used to encourage tissue and organ regeneration.

CONCLUSION
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While SDD is currently the only FDA-approved host modulation therapy for periodontitis, the success of using
host modulation therapy in the treatment of other chronic in ammatory diseases proves that host

12,17

modulation may be effective in controlling the immune response responsible for periodontal diseases.

Targeting the in ammatory pathways that lead to dysbiosis and chronic in ammation is ideal to reduce
tissue destruction related to host immunoin ammatory activity. Cytokine pathways may provide future drug
targets that will modify the host’s immune response in periodontal diseases, but thus far have only been
studied with other autoimmune diseases. Data regarding outcomes for periodontitis are still largely
unknown. More research is needed on the effects of host modulation therapies speci cally on periodontal
5

diseases. Currently, the side effects associated with host modulation medications for RA preclude their
safe use in patients exclusively with periodontal diseases. In the future, additional research may yield safer
drugs, dosages, and/or delivery methods that can also treat periodontitis.
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